caa a22 4500 445332271 CHVBK 20180317142741.0 cr unu---uuuuu 170323e20110601xx s 000 0 eng 10.1007/s10198-010-0241-7 doi (NATIONALLICENCE)springer-10.1007/s10198-010-0241-7 Deriving reference values and utilities for the QoL-AGHDA in adult GHD [Elektronische Daten] [J. Busschbach, B. Wolffenbuttel, L. Annemans, W. Meerding, M. Kołtowska-Häggström] Background: Quality of life (QoL) measures are important in growth hormone (GH) deficiency (GHD) in adults. Ideally, for use in health economics, QoL should be expressed in utilities. The aim of this study was to obtain reference values and utilities for QoL of GHD in adults in Belgium and the Netherlands. Methods: The study was conducted in three stages: (1) The Quality of Life-Assessment for Growth Hormone Deficiency in Adults (QoL-AGHDA) and the EQ-5D were administered in a representative sample of 6,875 individuals from the Belgian and 1,400 individuals from the general Dutch population. The EQ-5Dindex can be used to estimate utilities. Using a regression, utilities were predicted from the QoL-AGHDA. (2) QoL-AGHDA scores were obtained from 299 Belgian and 234 Dutch adult patients with GHD and no GH replacement. These scores were converted to utilities and compared the burden of disease with other patient groups. (3) To test the criterion validity, the ‘standard' EQ-5Dindex was used in a subsample of 64 Dutch GHD patients and compared with the predicted utilities. Results: We obtained data from 1,026 Belgian (response rate=15%) and 1,038 Dutch respondents (response rate=74%). The Belgian mean QoL-AGHDA value was 6.95 (90% range=14.00), and the Dutch mean was 5.48 (range=13.00). The R 2 of the regression model to predict the EQ-5Dindex was 0.360 (Belgium) and 0.482 (the Netherlands). We demonstrated a considerable burden of disease in GHD patients, comparable to patients with hypertension or with type II diabetes. The criterion validity was 0.407 (intraclass correlation, ICC). Conclusions: Interventions in GHD can now be evaluated more validly in Belgium and the Netherlands. The Author(s), 2010 Growth hormone/*deficiency nationallicence Quality of life nationallicence Quality-adjusted life years nationallicence Questionnaires nationallicence Reference values nationallicence Busschbach J. Medical Psychology and Psychotherapy, Erasmus MC, P.O. Box 2040, 3000 CA, Rotterdam, The Netherlands aut Wolffenbuttel B. Department of Endocrinology, University Medical Centre Groningen, University of Groningen, HPC AA31, P.O. Box 30001, 9700 RB, Groningen, The Netherlands aut Annemans L. Department of Public Health, Faculty of Medicine and Health Sciences, Ghent University, De Pintelaan 185 Bl.A-1, 9000, Ghent, Belgium aut Meerding W. Pfizer BV, Rivium Westlaan 142, 2909 LD, Capelle a/d IJssel, The Netherlands aut Kołtowska-Häggström M. KIMS Medical Outcomes, Pfizer Endocrine Care, Vetenskapsvägen 10, SE-191 90, Sollentuna, Sweden aut The European Journal of Health Economics Springer-Verlag 12/3(2011-06-01), 243-252 1618-7598 12:3<243 2011 12 10198 https://doi.org/10.1007/s10198-010-0241-7 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s10198-010-0241-7 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Busschbach J. Medical Psychology and Psychotherapy, Erasmus MC, P.O. Box 2040, 3000 CA, Rotterdam, The Netherlands aut NATIONALLICENCE 700 1- Wolffenbuttel B. Department of Endocrinology, University Medical Centre Groningen, University of Groningen, HPC AA31, P.O. Box 30001, 9700 RB, Groningen, The Netherlands aut NATIONALLICENCE 700 1- Annemans L. Department of Public Health, Faculty of Medicine and Health Sciences, Ghent University, De Pintelaan 185 Bl.A-1, 9000, Ghent, Belgium aut NATIONALLICENCE 700 1- Meerding W. Pfizer BV, Rivium Westlaan 142, 2909 LD, Capelle a/d IJssel, The Netherlands aut NATIONALLICENCE 700 1- Kołtowska-Häggström M. KIMS Medical Outcomes, Pfizer Endocrine Care, Vetenskapsvägen 10, SE-191 90, Sollentuna, Sweden aut NATIONALLICENCE 773 0- The European Journal of Health Economics Springer-Verlag 12/3(2011-06-01), 243-252 1618-7598 12:3<243 2011 12 10198 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer